Skip to main content

Chugai Pharmaceutical Co., Ltd. (CHGCY)

OTCMKTS: CHGCY · Delayed Price · USD
18.87 -0.10 (-0.50%)
Sep 22, 2021 3:57 PM EDT - Market closed
Market Cap64.42B
Revenue (ttm)809.06B
Net Income (ttm)n/a
Shares Out3.29B
EPS (ttm)0.63
PE Ratio29.80
Forward PE28.09
Dividend$0.27 (1.45%)
Ex-Dividend DateJun 28, 2021
Volume48,217
Open18.53
Previous Close18.96
Day's Range18.53 - 18.97
52-Week Range17.64 - 29.32
Beta0.62
Analystsn/a
Price Targetn/a
Est. Earnings DateOct 22, 2021

About CHGCY

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product...

IndustryDrug Manufacturers-General
Founded1925
CEOTatsuro Kosaka
Employees7,555
Stock ExchangeOTCMKTS
Ticker SymbolCHGCY
Full Company Profile

News

There is no news available yet.